Diamyd Medical’s investment will give a 20% ownership and a board seat in MainlyAI. The investment will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where a first project is sustainable production within the pharmaceutical sector.

Diamyd Medical is in a very exciting phase of development right now, the company has provided strong clinical data verifying the potential of the treatment targeting an identified genetic HLA group of individuals with type 1 diabetes, and is planning for the clinical phase III trial. Photo of Maja Johansson. Photographer: Andreas Nilsson

Ägare, Kapital.%, Röster.%. Anders Essen-Möller, 12,90%, 34,60%. Avanza Pension, 13,40%, 10,00%. Bertil Lindkvist, 9,00%, 6,80%. Nordnet Diamyd Medical CEO Comments, Quarterly Report 2 20/21, March 25, 2021. such as drug development and Precision Medicine applications, MainlyAI's expertise Besides our recent investment in MainlyAI, we have also employed our first av C Widén · 2010 — företag inom läkemedelsbranschen med forskning, utveckling och tillverkning i egen regi.

Diamyd medical makes an investment in mainly

Diamyd Medical’s investment will give a 20% ownership and a board seat in MainlyAI. The investment will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where a first project is sustainable production within the pharmaceutical sector. Diamyd Medical with MainlyAI and KTH awarded VINNOVA funding for AI driven sustainable production. Diamyd Medical together with MainlyAI AB and KTH Royal Institute of Technology have been awarded funding by the Swedish Governmental Innovation Agency VINNOVA for a project that will design, test and build a sustainability framework powered by artificial intelligence (AI) for Diamyd Medical’s production facility in Umeå, Sweden. Diamyd Medical AB: Diamyd Medical makes an investment in MainlyAI As announced in December 2020, Diamyd Medical and MainlyAI are, together with the Royal Institute of Technology (KTH), engaged in a VINNOVA funded project to design, test and build a sustainability framework powered by artificial intelligence for Diamyd Medical’s production facility in Umeå, Sweden. Diamyd Medical’s investment will give a 20% ownership and a board seat in MainlyAI.

DMYD B, Diamyd Medical B, (SE0005162880) Trading; Overview; Performance; Key Ratios; Financials; Fact Sheet ; Company Fact Sheet FAQ & Methodology ; REAL-TIME CET 04 Mar 2021 Diamyd Medical AB receives guidance from the US FDA , EMA for phase III trial in Type 1 diabetes mellitus 04 Mar 2021 Diamyd plans a phase III trial in Type 1 diabetes (In Children, In adolescents, In adults) to support the accelerated approval process in the US and Europe (Intralymphatic, Injection) in 2021 If you are looking for stocks with good return, Diamyd Medical B can be a profitable investment option. Diamyd Medical B quote is equal to 25.950 SEK at 2021-02-17. Based on our forecasts, a long-term increase is expected, the "DMYD-B" stock price prognosis for 2025-08-04 is 62.013 SEK. Company profile page for DIAMYD MEDICAL AB including stock price, company news, press releases, executives, board members, and contact information Diamyd Medical AB is a Sweden-based diabetes company.

Diamyd Medical’s investment will give a 20% ownership and a board seat in MainlyAI. The investment will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where a first project is sustainable production within the pharmaceutical sector.

Diamyd Medical has announced that the company has increased its investment in the associated company Cellaviva with an additional SEK 1.3 million. Close Sidebar Latest News

Diamyd medical makes an investment in mainly

diamyd medical: investerar 1,2 mln kr i mainly ai STOCKHOLM (Nyhetsbyrån Direkt) Forskningsbolaget Diamyd Medical investerar 1,2 miljoner kronor i Mainly AI, vilket ger en ägarandel på 20 procent i bolaget.

The investment of SEK 1.2 million will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where the first project is sustainable production within the pharmaceutical sector. Diamyd Medical makes an investment in MainlyAI Mon, Feb 22, 2021 08:45 CET The investment of SEK 1.2 million will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where the first project is sustainable production within the pharmaceutical sector. Diamyd Medical makes an investment in MainlyAI (Cision) 2021-02-22 08:45 The investment of SEK 1.2 million will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where the first project is sustainable production within the pharmaceutical sector. "Diamyd Medical makes an investment in MainlyAI" (news.cision.com) Published Mar 05, 2021 "Diamyd Medical makes an investment in MainlyAI" (news.cision.com) KTH and sustainability in other media. Page responsible: sustainability@kth.se. Belongs to: About KTH Last changed: Mar 05, 2021.

1994. 1997. 3. n.a..

About MainlyAI MainlyAI is a research Ulf Hannelius, CEO of Diamyd Medical will, following the investment, join MainlyAI's Board of Directors. About MainlyAI MainlyAI is a research 2021-02-22, Diamyd Medical, Diamyd Medical AB: Diamyd Medical makes an investment in Som meddelades i december 2020 är Diamyd Medical och MainlyAI för Diamyd Medical, kommer efter investeringen att ingå i MainlyAIs styrelse.
Ams billing

pt utbildning jonkoping
personlig swot analys mall
swedbank personkonto
kan frimärken gå ut
omx öppettider idag
sömn sagor
grankvist meaning

Issuu is a digital publishing platform that makes it simple to publish magazines, LIF, Business Region Sweden, Lund University, Invest in Skåne, Medicon Village, Vetenskapsrådet, monitors ethical guidelines, especially for medical Diamyd Medical AB (publ) Stockholm • Drug Development • Diabetes.

The investment is made within the framework of a convertible loan of SEK 2.7 million, mainly directed at existing shareholders.